AGIO - CIK 0001439222
AGIOS PHARMACEUTICALS, INC. trades as AGIO and has a market capitalization of $1.71 B, making it the #2223 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $54.03M, up 48.0% from the prior year and net income of -$413.00M. This page tracks AGIOS PHARMACEUTICALS, INC. through 1,268 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years AGIOS PHARMACEUTICALS, INC.'s revenue declined from $69.89M to $54.03M, a compound annual decline rate of 2.8%. Net profit margin compressed from -284.0% to -764.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-06 |
| SCHEDULE 13G | - | 2026-04-29 |
| Quarterly report | 10-Q | 2026-04-29 |
| Major company event | 8-K | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-24 |
| Proxy statement | DEF 14A | 2026-04-24 |
Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor
Results did not meet predefined threshold to support further development in LR-MDS
PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway
The largest companies sharing AGIOS PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
AGIOS PHARMACEUTICALS, INC. (AGIO) has a market capitalization of $1.71 B as of 2026-06-10, ranking #2223 among US-listed companies.
AGIOS PHARMACEUTICALS, INC. reported revenue of $54.03M for fiscal year 2025, an increase of 48.0% year over year.
In its latest fiscal year AGIOS PHARMACEUTICALS, INC. reported a net loss of $413.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.